Conrad Russell Y. Cruz
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Conrad Russell Y. Cruz has a total of 163 co-authors. Here are the top co-authors by number of shared publications:
- Catherine M. Bollard
Children's National Hospital and the George Washington University Washington DC USA
10 shared publications Catherine M. Bollard
Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA
6 shared publicationsHaili Lang
Center for Cancer and Immunology Research, and Division of Biostatistics and Study Methodology, Children's National Hospital, Washington, DC, USA
6 shared publicationsAshley Geiger
Center for Cancer and Immunology Research, Children's National Hospital, Washington, DC, USA
5 shared publicationsFahmida Hoq
Children’s National Hospital, Washington, USA
5 shared publications- Patrick J. Hanley
Children’s National Hospital, Washington, USA
5 shared publications
Latest Publications
- Open Access
- 22 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3493
Author Correction: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
- 22 July 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3493
Open AccessAuthor Correction: Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
- Open Access
- 30 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 2481-2493
Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Central nervous system (CNS) tumors are the deadliest cancers in children, highlighting the need for new therapies. The tumor-associated antigens (TAAs) WT1, PRAME and survivin are widely expressed by these tumors, and a manufacturing technique has been developed to target these intracellular TAAs using autologous, nongenetically engineered T cells. Here we therefore conducted ReMIND, an open-label, phase 1 adaptive dose-finding study to determine the safety/feasibility of autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin in children with CNS tumors. Eligible patients had newly diagnosed diffuse intrinsic pontine glioma without lymphodepletion (arm A, n = 16 enrolled, n = 11 infused) and relapsed/recurrent nonbrainstem CNS malignancies without (arm B, n = 28 enrolled, n = 18 infused) or with (arm C, n = 7 enrolled, n = 4 infused) lymphodepletion. Primary end points were safety, feasibility and maximum tolerated dose determination; secondary end points included preliminary efficacy and immunobiological correlates, including in vivo TAA-T persistence and systemic immune activation. Dose level 3 (8 × 107 cells per m2 per dose) was determined as the maximum tolerated dose. Treatment was well tolerated with fatigue and headache being the most common adverse events, although two possibly related serious adverse events of tumor swelling occurred. One grade 5 event in a patient with diffuse intrinsic pontine glioma with hydrocephalus, tumor edema and respiratory failure was categorized as a dose-limiting toxicity. Median overall survival for arm A was 13.7 months from diagnosis (range, 6.2-32.0) and median progression-free survival for arms B/C was 5.0 months from infusion (range, 0.5-51.6). Three patients in arms B/C are alive without disease at 31.8, 41.2 and 51.6 months without further treatment, including one complete response. This trial met safety/feasibility primary end points with some preliminary signals of efficacy. ClinicalTrials.gov registration: NCT03652545 .
- 30 June 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (7) , 2481-2493
Open AccessMulti-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial
Central nervous system (CNS) tumors are the deadliest cancers in children, highlighting the need for new therapies. The tumor-associated antigens (TAAs) WT1, PRAME and survivin are widely expressed by these tumors, and a manufacturing technique has been developed to target these intracellular TAAs using autologous, nongenetically engineered T cells. Here we therefore conducted ReMIND, an open-label, phase 1 adaptive dose-finding study to determine the safety/feasibility of autologous, systemically administered trivalent T cells targeting WT1, PRAME and survivin in children with CNS tumors. Eligible patients had newly diagnosed diffuse intrinsic pontine glioma without lymphodepletion (arm A, n = 16 enrolled, n = 11 infused) and relapsed/recurrent nonbrainstem CNS malignancies without (arm B, n = 28 enrolled, n = 18 infused) or with (arm C, n = 7 enrolled, n = 4 infused) lymphodepletion. Primary end points were safety, feasibility and maximum tolerated dose determination; secondary end points included preliminary efficacy and immunobiological correlates, including in vivo TAA-T persistence and systemic immune activation. Dose level 3 (8 × 107 cells per m2 per dose) was determined as the maximum tolerated dose. Treatment was well tolerated with fatigue and headache being the most common adverse events, although two possibly related serious adverse events of tumor swelling occurred. One grade 5 event in a patient with diffuse intrinsic pontine glioma with hydrocephalus, tumor edema and respiratory failure was categorized as a dose-limiting toxicity. Median overall survival for arm A was 13.7 months from diagnosis (range, 6.2-32.0) and median progression-free survival for arms B/C was 5.0 months from infusion (range, 0.5-51.6). Three patients in arms B/C are alive without disease at 31.8, 41.2 and 51.6 months without further treatment, including one complete response. This trial met safety/feasibility primary end points with some preliminary signals of efficacy. ClinicalTrials.gov registration: NCT03652545 .
- Open Access
- 15 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4510
Autologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study
Novel cellular therapies may enable HIV control or cure. HIV-specific T cells targeting conserved immunogenic protein regions of HIV Gag/Pol and the entirety of HIV Nef, termed HST-NEETs, eliminate HIV infected cells in vitro. Here we enroll seven participants in an open-label, single-arm phase 1 study (NCT03485963) to evaluate the safety (primary endpoint) of two autologous administrations of HST-NEET products without prescribed lymphodepletion. Adults with well-controlled HIV on anti-retroviral therapy are eligible. Six participants completed safety monitoring. No serious product-related toxicities are observed. Secondary endpoints are to assess expansion and persistence of HIV-reactive T cell clones, and changes to the HIV reservoir for each infused participant. HIV-specific T cell and HIV anti-Env antibody responses increase in two participants after infusion two. A trend towards decreasing levels of intact proviruses is observed in 2 participants. Three participants show persistence of HIV-reactive, product-associated T cell clones for ≥40 weeks post infusions. HST-NEETs infusions are well-tolerated. Future trials are needed to evaluate the efficacy of HST-NEETs in this population.
- 15 May 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 4510
Open AccessAutologous HIV-specific T cell therapy targeting conserved epitopes is well-tolerated in six adults with HIV: an open-label, single-arm phase 1 study
Novel cellular therapies may enable HIV control or cure. HIV-specific T cells targeting conserved immunogenic protein regions of HIV Gag/Pol and the entirety of HIV Nef, termed HST-NEETs, eliminate HIV infected cells in vitro. Here we enroll seven participants in an open-label, single-arm phase 1 study (NCT03485963) to evaluate the safety (primary endpoint) of two autologous administrations of HST-NEET products without prescribed lymphodepletion. Adults with well-controlled HIV on anti-retroviral therapy are eligible. Six participants completed safety monitoring. No serious product-related toxicities are observed. Secondary endpoints are to assess expansion and persistence of HIV-reactive T cell clones, and changes to the HIV reservoir for each infused participant. HIV-specific T cell and HIV anti-Env antibody responses increase in two participants after infusion two. A trend towards decreasing levels of intact proviruses is observed in 2 participants. Three participants show persistence of HIV-reactive, product-associated T cell clones for ≥40 weeks post infusions. HST-NEETs infusions are well-tolerated. Future trials are needed to evaluate the efficacy of HST-NEETs in this population.
- Open Access
- 5 June 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (7) , 718-727
Engineered tumor-specific T cells using immunostimulatory photothermal nanoparticles
- 5 June 2023
- Published by Elsevier in Cytotherapy
- Vol. 25 (7) , 718-727
Open AccessEngineered tumor-specific T cells using immunostimulatory photothermal nanoparticles
- Open Access
- 21 October 2022
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 27, 415-430
Co-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β
- 21 October 2022
- Published by Elsevier in Molecular Therapy - Methods & Clinical Development
- Vol. 27, 415-430
Open AccessCo-transducing B7H3 CAR-NK cells with the DNR preserves their cytolytic function against GBM in the presence of exogenous TGF-β
- Open Access
- 16 May 2022
- Published by Elsevier in Cytotherapy
- Vol. 24 (8) , 802-817
Comparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy
- 16 May 2022
- Published by Elsevier in Cytotherapy
- Vol. 24 (8) , 802-817
Open AccessComparable transforming growth factor beta-mediated immune suppression in ex vivo-expanded natural killer cells from cord blood and peripheral blood: implications for adoptive immunotherapy
- Open Access
- 8 February 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (6) , 2130-2152
The generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
- 8 February 2022
- Published by Elsevier in Molecular Therapy
- Vol. 30 (6) , 2130-2152
Open AccessThe generation and application of antigen-specific T cell therapies for cancer and viral-associated disease
- Open Access
- 28 October 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (2) , 279-281
Antigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort
- 28 October 2021
- Published by Springer Nature in Bone Marrow Transplantation
- Vol. 57 (2) , 279-281
Open AccessAntigen-specific T cell responses correlate with decreased occurrence of acute GVHD in a multicenter contemporary cohort
- 2 September 2021
- Published by Elsevier in Cytotherapy
- Vol. 24 (1) , 10-15
Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains
- 2 September 2021
- Published by Elsevier in Cytotherapy
- Vol. 24 (1) , 10-15
Spike-directed vaccination elicits robust spike-specific T-cell response, including to mutant strains
- Open Access
- 19 April 2021
- Published by Springer Nature in Research Square
Spike-Directed Vaccination Elicits Robust Spike-Specific T cell Responses Including to Mutant Strains
While most studies describing COVID-19 vaccine responses have focused on antibodies, there is increasing evidence that T cells play a critical role. Here we evaluated T cell responses in seronegative donors before and after vaccination to define responses to SARS-CoV-2 reference strain, as well as to mutations in the variant strains B.1.1.7 and B.1.351. We observed enhanced T cell responses to reference and variant Spike strains post vaccination.
- 19 April 2021
- Published by Springer Nature in Research Square
Open AccessSpike-Directed Vaccination Elicits Robust Spike-Specific T cell Responses Including to Mutant Strains
While most studies describing COVID-19 vaccine responses have focused on antibodies, there is increasing evidence that T cells play a critical role. Here we evaluated T cell responses in seronegative donors before and after vaccination to define responses to SARS-CoV-2 reference strain, as well as to mutations in the variant strains B.1.1.7 and B.1.351. We observed enhanced T cell responses to reference and variant Spike strains post vaccination.